Acrux (ASX:ACR)
ASX announcement history & article coverage
Transparent by design.
Announcments by Acrux (ASX:ACR) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Application for quotation of securities - ACR
Notice of Extraordinary General Meeting/Proxy Form
Appendix 3Y Oldham
Appendix 3Y Dobinson
Appendix 3Y Brumley
Application for quotation of securities - ACR
Notification of cessation of securities - ACR
Application for quotation of securities - ACR
Update - Licensing Lenzetto for Australia for AUD5.4m
Acrux licenses Lenzetto® for Australia with AUD 5.4 million milestone deal
Acrux licenses Lenzetto for Australian market for AUD5.4m
Acrux secures AUD 5.4 million milestone deal for Lenzetto® to address Australian menopause therapy shortage
Cleansing Notice
Application for quotation of securities - ACR
Capital Gains Tax exemptions remain in place for Acrux
Acrux Capital Gains Tax Exemptions Unaffected by 2026/27 Federal Budget Changes
Proposed issue of securities - ACR
Acrux raises $1.6 million via Share Placement
Acrux raises $1.6 million via discounted share placement with attaching options
Trading Halt
Quarterly Activities/Appendix 4C Cash Flow Report
Acrux advances female testosterone Phase III trials with strong revenue growth and funding strategies
Acrux strategy focuses on Female Testosterone for low libido
Acrux pivots to Female Testosterone therapy for HSDD with co-development strategy and FDA pathway
